Meloxicam Market Share

  • Report ID: 5360
  • Published Date: Nov 02, 2023
  • Report Format: PDF, PPT

Meloxicam Market Share

North American Market Forecasts

The meloxicam market in North America region is anticipated to account for the largest revenue share of 33% by the end of the forecast period. The growth of this market can be primarily driven by an increasing number of arthritis and other chronic pain disease patients found in this region. Besides, increasing healthcare infrastructure and escalating research and development activities in meloxicam are driving the market expansion further in the North America region during the projected period. An estimated 58.5 million US adults have been told by their doctor that they have some form of arthritis, rheumatoid arthritis, gout, lupus or fibromyalgia, based on data from the National Health Interview Survey between 2016 and 2018.

APAC Market Statistics

The meloxicam market in the Asia Pacific region is estimated to account for a notable revenue share during the forecast period. This growth can be attributed to high product demand due to the growing aging population and the increasing incidence of osteoarthritis, rheumatoid arthritis, soft tissue inflammation, traumatic pain and post-operative pain. Also, there has been surging demand for rheumatoid arthritis treatment in the region. Additionally, regional growth over the forecast period is expected to be driven by favorable reimbursement policies for generic drugs. All these factors are predicted to drive the market growth of meloxicam in the APAC region during the studied period.

Research Nester
Meloxicam Market Size

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 5360
  • Published Date: Nov 02, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The growing prevalence of chronic pain disease and increasing research and development in meloxicam are some of the major factors anticipated to drive the growth of the meloxicam market.

The market is anticipated to attain a CAGR of ~5% over the forecast period, i.e., 2024-2036.

The major players in the market are of Healthy Life Pharma Private Limited., EPICON LIFESCIENCES LLP, Boehringer Ingelheim GmbH., Baudax Bio, Heron Therapeutics Inc., Avanstra Inc., PD-Rx Pharmaceuticals, Inc., and others.

The osteoarthritis segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in North America is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying